

Ayurveda, Homeopathy and Chinese Medicine

May 18-19, 2017 Munich, Germany

Homeopathy: Curative Cancer Treatment Potential

Oroma B Nwanodi
Locum Tenens, USA

Background: Homeopathy is used by 12 to 24% of European cancer patients, representing 40.4% of patients at European integrative cancer centers. In 2011, a Swiss review of the literature on homeopathy led to homeopathic treatment coverage in the Swiss national health insurance program. Homeopathy for curative pediatric cancer treatment is limited to 7.4% in the Netherlands, but, 76.5% of German parents will use homeopathy as part of their children's cancer treatment. Homeopathy may be ready to play a larger role in curative cancer treatment.

Methods: PubMed searches in September 2016 and January 2017, and google scholar searches in August 2016 were performed with search terms "homeopathy or nutraceuticals or phytochemicals cancer treatment" from 2012 onwards. Curative homeopathic treatments were taken from these searches. Supplemental specific hand searches were performed as needed.

Findings: Corroborating studies are needed for the Prasanta Banerji Homeopathic Research Foundation standalone ultramolecular glioma treatment protocol, Ruta graveolens 6c and Calcerea phosphorica 3X. Ultramolecular Carcinosis, Phytolacca decandra, Conium, Thuja and Klimaktoplan® may be appropriate for in vivo breast cancer trials. Lycopodium clavatum 5C and 15C should be considered for in vivo cervical cancer trials. Sulphur 30C, may be considered for non-small cell lung adenocarcinoma treatment trials. The Critical Cancer Management Research Centre & Clinic Psorinum-6x formulation could undergo confirmatory trials for gallbladder, lung, oral, pancreatic, stomach, periampullary and liver adenocarcinomas.

Conclusion & Significance: *In vitro* studies and retrospective case series indicate that homeopathy could provide curative cancer treatment for an array of cancers: Breast, cervix, gallbladder, liver, lung, oral, pancreas, periampullary, skin, and stomach. Appropriately designed randomized controlled trials (RCT) based on reproducible homeopathic formulations and clinical protocols, and incorporating intention-to-treat analysis will have increased validity. If these RCT are accomplished with positive outcomes, homeopathy may secure a position in curative cancer treatment.

Biography

Oroma B Nwanodi graduated from Meharry Medical College of Nashville, Tennessee in the United States of America as a Medical Doctor in 2001. She specialized in Obstetrics and Gynecology at The University of Massachusetts and Maimonides Medical Center. In 2013 and 2014, she obtained specialization in Integrative Holistic Medicine. In 2016, she completed the Doctor of Health Science program at A T Still University, Mesa, Arizona. She has practiced in California, Missouri, Minnesota, and Wyoming.

o.nwanodi@juno.com

Notes: